좋CHEST

Pressure-Controlled vs Volume-Controlled Ventilation in Acute Respiratory Failure A Physiology-Based Narrative and Systematic Review

Nuttapol Rittayamai, MD; Christina M. Katsios, MD; François Beloncle, MD; Jan O. Friedrich, MD, PhD; Jordi Mancebo, MD; and Laurent Brochard, MD

BACKGROUND: Mechanical ventilation is a cornerstone in the management of acute respiratory failure. Both volume-targeted and pressure-targeted ventilations are used, the latter modes being increasingly used. We provide a narrative review of the physiologic principles of these two types of breath delivery, performed a literature search, and analyzed published comparisons between modes.

METHODS: We performed a systematic review and meta-analysis to determine whether pressure control-continuous mandatory ventilation (PC-CMV) or pressure control-inverse ratio ventilation (PC-IRV) has demonstrated advantages over volume control-continuous mandatory ventilation (VC-CMV). The Cochrane tool for risk of bias was used for methodologic quality. We also introduced physiologic criteria as quality indicators for selecting the studies. Outcomes included compliance, gas exchange, hemodynamics, work of breathing, and clinical outcomes. Analyses were completed with RevMan5 using random effects models.

RESULTS: Thirty-four studies met inclusion criteria, many being at high risk of bias. Comparisons of PC-CMV/PC-IRV and VC-CMV did not show any difference for compliance or gas exchange, even when looking at PC-IRV. Calculating the oxygenation index suggested a poorer effect for PC-IRV. There was no difference between modes in terms of hemodynamics, work of breathing, or clinical outcomes.

CONCLUSIONS: The two modes have different working principles but clinical available data do not suggest any difference in the outcomes. We included all identified trials, enhancing generalizability, and attempted to include only sufficient quality physiologic studies. However, included trials were small and varied considerably in quality. These data should help to open the choice of ventilation of patients with acute respiratory failure. CHEST 2015; 148(2):340-355

Manuscript received December 17, 2014; revision accepted April 1, 2015; originally published Online First April 30, 2015.

ABBREVIATIONS: APRV = airway pressure release ventilation; ARF = acute respiratory failure; CMV = continuous mandatory ventilation; Crs = respiratory system compliance; IMV = intermittent mandatory ventilation; I:E = inspiratory to expiratory; PC = pressure control; PEEP = positive end-expiratory pressure; PEEPi = intrinsic positive end-expiratory pressure; PIF = Pao₂ to FIO₂; PIP = peak inspiratory pressure; PL = transpulmonary pressure; Pplat = plateau pressure; PSV = pressure support ventilation; TE = expiratory time; TI = inspiratory time; VC = volume control; VT = tidal volume

AFFILIATIONS: From the Li Ka Shing Knowledge Institute and Critical Care Department (Drs Rittayamai, Beloncle, Friedrich, and Brochard), St. Michael's Hospital, Toronto, ON, Canada; Interdepartmental Division of Critical Care Medicine (Drs Rittayamai, Katsios, Beloncle, Friedrich,

and Brochard), University of Toronto, Toronto, ON, Canada; Division of Respiratory Diseases and Tuberculosis (Dr Rittayamai), Department of Medicine, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand; Medical Intensive Care Unit (Dr Beloncle), Hospital of Angers, Université d'Angers, Angers, France; Servei de Medicina Intensiva (Dr Mancebo), Hospital Sant Pau, Barcelona, Spain; and Keenan Research Centre (Dr Brochard), St. Michael's Hospital, Toronto, ON, Canada.

FUNDING/SUPPORT: The authors have reported to *CHEST* that no funding was received for this study.

CORRESPONDENCE TO: Laurent Brochard, MD, St. Michael's Hospital, 30 Bond St, Toronto, ON, M5B 1W8, Canada; e-mail: brochardl@smh.ca © **2015 AMERICAN COLLEGE OF CHEST PHYSICIANS.** Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details. **DOI:** 10.1378/chest.14-3169

Acute respiratory failure (ARF) is common in critically ill patients admitted to ICUs and often culminates in mechanical ventilation as respiratory support. Mechanical ventilation is the cornerstone of management, with invasive positive pressure ventilation remaining the most common method of gas delivery. A ventilator breath can be achieved in two ways: flow/volume targeting (volume control [VC]) or pressure targeting (or pressure control [PC]) with either time or flow cycling.¹ Then the ventilator delivers three basic breath sequences including continuous mandatory ventilation (CMV), intermittent mandatory ventilation (IMV), and continuous spontaneous ventilation.² In the past decade, VC-CMV remained the most common mode of ventilation during the first few days of mechanical ventilation. Large international observational studies demonstrated that VC-CMV was used in approximately 60% of critically ill patients,3 but that its use has decreased over time to 40%.^{4,5} Data from the most recent international prospective cohort study demonstrated that PC breath (using different modes) use has increased from 7% to 20% in 2010 as the initial mode (PC-CMV), and that after 48 h of mechanical ventilation, pressure-targeted modes (PC-CMV, PC-IMV, and pressure support ventilation [PSV]) are now preferentially used.5

PC-CMV is one of several types of pressure-targeted modes of ventilation, which include PC-IMV, airway pressure release ventilation (APRV), biphasic positive airway pressure, PSV, and pressure-regulated VC ventilation.² Unfortunately, the nomenclature of pressuretargeted modes is often specific to each ventilator brand (e-Table 1). In addition, the basic principles regarding the breath types and modes are not always well understood and erroneous claims about potential advantages for each mode are still frequently made, such as emphasizing the differences in peak airway pressure.

Our study reviews the physiologic principles surrounding PC and VC breaths. Subsequently, we present a literature search in the form of a systematic review and meta-analysis comparing the physiologic effects and the clinical outcomes of PC-CMV, PC-inverse ratio ventilation (IRV), and VC-CMV in patients with ARF.

Working Principles and Physiology of PC and VC Breaths

Working Principles

A PC breath is patient-triggered or time-triggered, pressure-limited and usually time-cycled or flow-cycled. In PC-CMV, set ventilatory variables include inspira-

tory pressure, inspiratory time (TI) or fraction (inspiratory to expiratory [I:E] ratio), pressure rise time, and respiratory rate; set variables that affect mainly oxygenation include positive end-expiratory pressure (PEEP) and FIO2.6 The volume and flow in PC-CMV are dependent variables⁷ and vary with both respiratory mechanics and patient effort. During the inspiratory phase, flow is rapidly provided by the ventilator until reaching a value close to the preset pressure, at which point the ventilator tries to maintain this pressure constant and flow gradually decreases according to the preset pressure level and the mechanical properties of the respiratory system until the end of inspiration.8 The pressure waveform during inspiration is virtually constant (square) and the flow waveform is one of decelerating flow.9 When and only when TI is long enough for flow to reach zero, the preset pressure is in equilibrium with the peak alveolar pressure at the end of the breath and equals the so-called plateau pressure (Pplat). With PC-CMV, the peak inspiratory pressure (PIP) is guaranteed by the ventilator and will not exceed the preset pressure limit. If the inspiratory flow does not reach zero, the preset pressure is not equal to Pplat and this also affects delivered tidal volume (VT) (Fig 1). This has been claimed as a possible mechanism for minimizing the risk of alveolar overdistention and barotrauma.^{10,11} This, however, does not hold true as soon as the patient exerts some spontaneous activity (vide infra). The cycling from inspiration to expiration is determined by time. During expiration, the pressure is abruptly released and the lung is emptied by the passive recoil forces until the airway pressure is equal to the preset PEEP. If the expiratory time (TE) is long enough to reach a zero flow, the alveolar pressure will have the same PEEP value.

In VC-CMV, the breath can be patient-triggered or time-triggered by the ventilator. The ventilator then delivers the preset VT by using the same flow-time waveform in every breath.¹² The airway pressure is a dependent variable and is influenced by respiratory mechanics and patient's effort.¹³ Inspiratory flow pattern in VC-CMV is most frequently a square flow; other flow patterns can be used, including ramp (accelerating or decelerating) or sinusoidal in some ventilators.¹⁴ Other set variables include respiratory rate, and either TI or I:E ratio or the peak flow rate (volume and flow gives insufflation time), PEEP, and FIO₂. VC-CMV is cycled by time or volume. PIP in VC-CMV is the sum of the elastic and resistive pressures plus the initial pressure in the system during flow delivery. When the airway is



Figure 1 – The impact of inspiratory time on Pplat during pressurecontrolled breath. PIP is only equal to Pplat when inspiratory flow reaches zero because of the equilibrium with alveolar pressure. In addition, tidal volume increases in this condition. PIP = peak inspiratory pressure; Pplat = plateau pressure.

occluded at the end of inspiration and flow ceases, the airway pressure falls until it reaches Pplat, which reflect the elastic recoil pressure of the respiratory system.¹⁵

Passive Condition

Under passive conditions, the ventilator entirely substitutes the respiratory muscles for gas delivery. VT delivered under passive condition in VC-CMV is preset and theoretically constant,¹⁶ whereas VT in PC-CMV depends on three main factors: the driving pressure, the time constant of the respiratory system (ie, the product of compliance and resistance of the respiratory system), and Tr.

The driving pressure in PC breaths is the pressure difference between the PIP and total PEEP, which is the pressure in the alveoli at the very end of expiration, immediately before the insufflation starts.¹⁷ In PC-CMV, the delivered VT is proportional to the driving pressure.



Figure 2 – Pressure control-continuous mandatory ventilation mode with different inspiratory time (Tt) and expiratory time (TE). PEEPi increases when Tt increases with inadequate TE. This phenomenon leads to decreases in driving pressure and delivered tidal volume. PEEPi is measured by the pressure difference between the beginning of muscular pressure and the onset of inspiratory flow (pressure difference between two dotted lines). PEEPi = intrinsic positive end-expiratory pressure.



Figure 3 – Comparison between two levels of muscular pressure in pressure control (PC) breath with the same airway pressure and volume control (VC) breath. Increasing muscular pressure leads to increase delivered tidal volume in PC breath whereas the tidal volume is constant in VC breath.

Intrinsic PEEP (PEEPi) is a condition during which end-expiratory lung volume remains above functional residual capacity as a result of dynamic hyperinflation.¹⁸ The usual mechanisms for developing PEEPi are increased expiratory resistance causing expiratory flow limitation, and high respiratory rate with inadequate TE.19 In PC-CMV, inadequate TE results in incomplete lung emptying and concomitant PEEPi (Fig 2). To prevent incomplete lung emptying, and in the absence of flow limitation, TE should theoretically be longer than three time constants.²⁰⁻²² PEEPi decreases the driving pressure and, thus, affects the delivered VT. When PEEPi increases, both the true driving pressure and the delivered VT decrease. This, for instance, can occur with increasing respiratory rate at constant TI, or with increasing expiratory resistance or compliance of the respiratory system at constant TE.^{23,24} This can explain the paradoxical effect of increasing the respiratory rate resulting in reduced delivered ventilation. The same physiologic

abnormality (PEEPi) will generate a progressive increase in Pplat during VC-CMV without affecting VT.

Furthermore, changes in compliance and resistance will affect the delivered VT in PC-CMV in most situations. The equation of motion of the respiratory system dictates that the driving pressure applied to the respiratory system consists of the pressure needed to overcome the elastance and the pressure dissipated against the resistance.²⁵ The elastance of the respiratory system (inverse of compliance) reflects the "stiffness" of the respiratory system and is influenced by the amount of aerated lung volume. For an identical VT, the lower the lung volume, the higher the elastance of the respiratory system. The clinician must be aware of this influence and monitor VT on the ventilator when using PC-CMV, especially in patients with restrictive diseases (eg, ARDS, chest wall stiffness, increased intraabdominal pressure) because VT may decrease as their disease worsens.^{23,26} The effect



Figure 4 – Responses to change from passive to active breathing. In VC-CMV, airway pressure drops when muscular pressure increases and PL is maintained. With PC-CMV, changing from passive to active breathing leads to increase in PL when airway pressure is constant. PC-CMV = pressure controlcontinuous mandatory ventilation; PL = transpulmonary pressure; VC-CMV = volume controlcontinuous mandatory ventilation.



of the resistance of the respiratory system to delivered VT is dependent on the flow rate and the diameter of endotracheal tube and airways, explaining that most of the resistive pressure is dissipated in the first part of the insufflation. This is why, in contrast with elastance, the effect of resistance on VT will vary depending on TI.²³ If flow is terminated early before the end of insufflation, increasing resistance will initially have no effect on VT; in other cases, it will decrease VT. An increased resistance may also act via its consequence on PEEPi as described previously, especially in the conditions of high respiratory rate and inadequate TE.^{8,19}

Finally, a relevant factor for VT delivery with a PC breath is the duration of inspiration. The maximum VT will occur when the lung is at complete inflation, meaning that the airway pressure equilibrates with alveolar pressure at zero flow. Complete inflation requires a TI longer than three time constants.^{8,20} This is why, frequently, the flow is still positive at the end of a usual inspiration (often lasting < 1 s). If inspiratory resistance increases, a longer TI is needed to complete inflation and keep the same VT.

Spontaneous Breathing or Partial Ventilatory Support

When the patient develops spontaneous breathing efforts and triggers the ventilator, the real driving pressure becomes the sum of the pressure generated by the ventilator and by the patient's inspiratory muscles.⁸ In Figure 5 - Comparison of three different pressure-targeted modes according to inspiratory synchronization (i-sync). Tracings of airway pressure, esophageal pressure, tidal volume, and transpulmonary pressure demonstrated that during fully i-sync mode (PC-CMV), all patient efforts triggered the ventilator. In partially i-sync mode (pressure control-intermittent mandatory ventilation [PC-IMV]) and non i-sync mode (airway pressure release ventilation [APRV]), two types of breaths (synchronized spontaneous and mandatory breath and spontaneous breath at positive end-expiratory pressure [PEEP] or low pressure) are observed. PC-CMV has more constant tidal volume and higher transpulmonary pressure than PC-IMV and APRV despite identical ventilator settings (inspiratory pressure = $20 \text{ cm } H_2O$ and $PEEP = 10 \text{ cm } H_2O$). See Figure 4 legend for expansion of other abbreviations.

this scenario, the muscular pressure (which remains hidden to the clinician) becomes an important part of the equation of motion. The physiology of PC-CMV markedly differs from the passive condition when spontaneous breathing activity is present.

In PC-CMV, the patient usually triggers the ventilator at each breath. There are two types of forces inflating the lung: the positive pressure delivered by the ventilator



Figure 6 – Search strategy. CENTRAL = Cochrane Central Register of Controlled Trials; EMBASE = Excerpta Medica dataBASE; MEDLINE = Medical Literature Analysis and Retrieval System Online.

1					
Study/Year	No. of Patients	Population	Study Intervention	Duration of Ventilation in Each Mode	Reported Outcomes
Randomized controlled study					
Rappaport et al ⁴¹ /1994	27	Acute hypoxic respiratory failure	VC-CMV and PC-CMV	At least 72 h	Crs, gas exchange, clinical outcomes
Esteban et al ¹⁰ /2000	79	ARDS (AECC criteria)	VC-CMV and PC-CMV	Until successful extubation	Crs, clinical outcomes
Castellana et al ^{so} /2003	61	Post coronary bypass graft surgery with acute hypoxemia	VC-CMV and PC-CMV	2 h	Gas exchange
Ge et al ⁵¹ /2004	20	ARDS	VC-CMV and PC-CMV	24 h	Crs, gas exchange, hemodynamics
Gritsan et al ^{s2} /2012	75	Hemorrhagic stroke	VC-CMV and PC-CMV	7 d	Crs, gas exchange, hemodynamics, clinical outcomes
Randomized crossover study					
Mercat et al ⁵³ /1993	10	ARDS with LIS > 2.5	VC-CMV, PC-CMV, and PC-IRV	1 h	Hemodynamics
Lessard et al54/1994	6	ARDS with LIS > 2.5	VC-CMV, PC-CMV, and PC-IRV	30 min	Crs, hemodynamics
Vallverdu et al ^{ss} /1994	8	ARDS with LIS > 2.5	VC-CMV and PC-IRV	30-45 min	Crs, gas exchange, hemodynamics
Mancebo et al ^{s6} /1994	8	ARDS with LIS > 2.5	VC-CMV and PC-IRV	At least 45 min	Crs, gas exchange, hemodynamics
Auler Júnior et al57/1995	20	Elective postcardiac surgery	VC-CMV and PC-CMV	15 min	Hemodynamics
			Group 1: cardiac index >2.5 L/min/m ² (10 patients)		
			Group 2: cardiac index <2.5 L/min/m² (10 patients)		
Cinnella et al³2/1996	13	Acute respiratory failure of different etiologies	Part 1 (7 patients): VC-CMV and PC-CMV (high and moderate VT with low inspiratory flow)	20 min	Gas exchange, hemodynamics, work of breathing
			Part 2 (6 patients): VC-CMV and PC-CMV (moderate VT with low and high inspiratory flow)		

TABLE 1] Patient Characteristics in the Included Studies

(Continued)

ontinued)	
<u>(</u>	
E 1	

	Reported Outcomes	Gas exchange, hemodynamics	Work of breathing	Crs, gas exchange	Gas exchange, work of breathing	Work of breathing		Gas exchange	Gas exchange, hemodynamics	Crs, gas exchange, hemodynamics	Gas exchange	Clinical outcomes		Gas exchange, hemodynamics	Crs, gas exchange, hemodynamics	Crs, gas exchange	Hemodynamics	Gas exchange, hemodynamics	Crs, gas exchange, hemodynamics	Gas exchange, hemodynamics
	Duration of Ventilation in Each Mode	2 h	30 min	15 min	N/A	20 min		48 h	24 h	12 h	N/A	Until extubation		N/A	60 min	30 min	30 min	1 h	30 min	20 min
	Study Intervention	VC-CMV (square and decelerating waveform) and PC-CMV	VC-CMV and PC-CMV	VC-CMV and PC-CMV	VC-CMV, PC-CMV, and PSV	VC-CMV, PC-CMV, and PRVC		VC-CMV and biphasic positive pressure ventilation	VC-CMV and PC-CMV	VC-CMV and PC-IRV	VC-CMV and PC-CMV	VC-CMV and PC-CMV		VC-CMV and PC-IRV	VC-CMV and PC-CMV	VC-CMV and PC-CMV	VC-CMV and PC-IRV	VC-CMV and PC-IRV	VC-CMV with and without PEEP and PC-IRV	VC-CMV, PC-CMV, and PC-IRV
	Population	ARDS	ARDS (AECC criteria)	Patients mechanically ventilated in the ICU	Patients mechanically ventilated in the ICU	ARDS (AECC criteria)		Leukopenic, ARDS with LIS>2.5	Traumatic ARDS	ARDS (AECC criteria)	Pulmonary contusion from blunt trauma	COPD with acute respiratory failure		Severe ARDS	Severe ARDS	Acute respiratory failure of different etiologies	ARDS with LIS > 2.5	Severe head injury (Glasgow Coma Scale < 8)	ARDS (AECC criteria)	Acute respiratory failure
	No. of Patients	25	18	114	7	14		20	40	14	21	40		31	10	11	12	6	8	6
TABLE 1] (continued)	Study/Year	Davis et al ³⁹ /1996	Kallet et al ⁴⁵ /2000	Castañón-González et al ³⁸ /2003	Chiumello et al ⁴⁶ /2002	Kallet et al ⁴⁷ /2005	Nonrandomized parallel study	Kiehl et al ⁵⁹ /1996	Yang et al∞/2005	Armstrong and MacIntyre ⁶¹ /1995	Sharma et al ⁶² /1996	Karakurt et al ⁶³ /2009	Nonrandomized crossover study	Tharratt et al ⁶⁴ /1988	Abraham and Yoshihara65/1990	Muñoz et al‱/1993	Poelaert et al67/1993	Clarke ⁶⁸ /1997	Zavala et alºº/1998	Jung et al‰/1999

TABLE 1] (continued)					
Study/Year	No. of Patients	Population	Study Intervention	Duration of Ventilation in Each Mode	Reported Outcomes
Kim et al ⁷¹ /1999	10	Acute respiratory failure	VC-CMV and PC-CMV with low VT (6-8 mL/kg) and high VT (10-12 mL/kg)	N/A	Work of breathing
Prella et al ⁴⁰ /2002	10	ARDS (AECC criteria)	VC-CMV and PC-CMV	30 min	Crs, gas exchange
Wang and Wei ⁷² /2002	20	ARDS with LIS > 2.5	VC-CMV and PC-IRV	N/A	Gas exchange
Yang et al ⁴⁴ /2007	12	Acute respiratory failure	VC-CMV and PC-CMV	1 h	Crs, hemodynamics
Razek et al ⁷³ /2008	50	Orthotropic liver transplantation patients	VC-CMV and PC-CMV at PEEP 5 and 10 cm H_2O	30 min	Crs, gas exchange, hemodynamics
Othman et al²4/2013	15	Severe head trauma patients	VC-CMV and PC-CMV	12 h	Gas exchange, hemodynamics
AECC = American European Consensus Confere PC-IRV = pressure control-inverse ratio ventilati.	nce; Crs = resp on; PEEP = pos	iratory system compliance; LIS = lung injury score; h sitive end-expiratory pressure; PRVC = pressure regul	N/A = not applicable; PC-CMV = pressure con lated volume control ventilation; PSV = press	ntrol-continuous mandatory sure support ventilation; VC-	ventilation; .CMV = volume control-

continuous mandatory ventilation; VT = tidal volume.

and the negative intrapleural pressure generated by the respiratory muscles.27 Because of this, the airway pressure displayed by the ventilator is not anymore a clinically valid surrogate of transpulmonary pressure (PL). If the patient is exerting strong respiratory efforts, the inspiratory PL increases without any change in airway pressure. With increased patient's efforts, VT will increase dramatically (Fig 3), and can become injurious to the lung if the patient's respiratory drive and muscle output are high. Risk of overdistension or large stretch injury could be particularly important in patients with ARDS or in those at risk for developing ARDS.²⁸⁻³⁰ This is different in VC-CMV because, in theory, VT remains constant despite increasing effort of the patient. In VC-CMV, the airway pressure drops from its passive trajectory as soon as intrathoracic pressure becomes negative, but PL is kept constant in this scenario (Fig 4). The drawback of this response in VC-CMV may be discomfort for the patient, also referred to air hunger due to inadequate flow and the patient's desire for higher flow early during the breath. It is highly dependent on the peak flow rate.^{31,32} This is also why an adequate peak-flow setting is so important for patient's comfort in VC-CMV when the patient triggers the ventilator.32 Setting the flow rate at 1 L/s is usually adequate for most of the patients.

Yoshida et al^{33,34} demonstrated in experimental models that strong spontaneous efforts can worsen lung injury by increasing PL and delivered regional VT. This injury can occur even when Pplat are limited below 30 cm H₂O because of regional PL increase causing pendelluft. The clinician should be cautious of using PC-CMV during lung protective ventilation in patients who are making substantial respiratory efforts. The use of PC-CMV in these patients may worsen the severity of lung injury. Richard et al³⁵ compared the different types of pressuretargeted modes (PC-CMV, PC-IMV, and APRV) in both bench and clinical studies. They used the same ventilator settings in all three modes and looked at the effects of the interaction with patient's simulated inspiratory activity. These modes have different working principles with respect to inspiratory synchronization between the patient and the ventilator. The fully synchronized mode (PC-CMV) had much higher VT and PL than partially synchronized (PC-IMV) and nonsynchronized (APRV) modes despite identical ventilator settings and levels of patient effort (Fig 5).

During PC-CMV, with some degree of spontaneous effort, the PIP can become lower than the alveolar pressure or the static recoil pressure at the end of inspiration (Pplat). In this situation, the PIP does not confer anymore protection against lung distention since the total distending pressure may become much higher.³⁶

Gas Exchange

From a physiologic standpoint, a decelerating flow pattern in PC-CMV could allow a different gas distribution than a square flow and initial studies had suggested a possible advantage in terms of gas exchange.^{10,37} Al-Saady and Bennett³⁸ suggested that a decelerating flow resulted in a lower airway resistance, higher compliance, and improvement of oxygenation when compared with a constant flow waveform. Davis et al³⁹ demonstrated that PC-CMV provided better oxygenation in 25 patients with ARDS when compared with VC-CMV with a square flow but at the expense of higher mean airway pressure. However, several other studies, with a better control of total PEEP and Pplat comparing PC-CMV (with normal I:E ratio) and VC-CMV with a square flow have not observed the purported benefits of PC-CMV in terms of gas exchange.32,40,41 Thus, the beneficial effect on gas exchange of PC-CMV compared with VC-CMV remains at best inconclusive.

Patient-Ventilator Interaction and Patient's Effort

In PC-CMV, the initial (peak) inspiratory flow rate is usually high at the beginning of inspiration and may more often and more easily overcome patient's demand than VC-CMV using a fixed flow pattern.²⁹ This is especially relevant in patients with high respiratory drive. A common problem of VC-CMV with a fixed flow pattern is the occurrence of insufficient flow delivery when the set inspiratory flow rate is lower than the peak patient's demand for flow.^{13,42} In particular, when using a low tidal volume strategy, PC-CMV may improve patient-ventilator synchrony.⁴³ Yang et al⁴⁴ demonstrated that PC-CMV improved the patient's trigger effort when compared with VC-CMV at the same VT (6-8 mL/kg ideal body weight) in patients with ARDS. The price to pay, however, is the loss of control of VT.

Cinnella et al³² compared PC-CMV with VC-CMV at both high and moderate VT. They found that PC-CMV reduced the work of breathing, transdiaphragmatic pressure swing, and pressure-time product at moderate VT (8 mL/kg) but only when the set peak flow during VC-CMV was insufficient. Indeed, they found that the same work of breathing could be achieved with one mode or another with properly adjusted settings (ie, similar flow rates in PC-CMV and VC-CMV). Kallet et al⁴⁵ also found that PC-CMV significantly reduced patient work of breathing relative to VC-CMV. The advantage of PC-CMV in terms of reducing patient work of breathing in both studies may be explained by the higher initial peak flow rate. However, when flow rates are similar between PC-CMV and VC-CMV, the work of breathing does not differ.46,47

Adjustment of the pressure rise time (ie, the rate of inspiratory valve opening) to match the patient's inspiratory flow demand could further improve patient effort. Pressure rise time is defined as how rapidly the inspiratory valve opens and hence how rapidly the pressure changes from its end-expiratory value to the preset

	PC-CM	V and PC	C-IRV	V	с-сму	,		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
23.37.1 Randomized	study								
Esteban 2000	31	13	37	29	9	42	17.6%	2.00 [-3.00, 7.00]	
Gritsan 2012	43.5	3	36	43.3	3.1	39	30.8%	0.20 [-1.18, 1.58]	+
Lessard 1994	28.5	8.7	18	28	10	9	10.8%	0.50 [-7.17, 8.17]	
Vallverdu 1994	48.4	11.9	8	44.4	14.3	8	4.9%	4.00 [-8.89, 16.89]	
Subtotal (95% CI)			99			98	64.1%	0.37 [-0.93, 1.68]	◆
Heterogeneity: Tau ² =	0.00; Chi ²	= 0.77, d	f = 3 (P	= 0.86);	$ ^{2} = 0^{0}$	%			
Test for overall effect:	Z = 0.56 (F	P = 0.58)							
23.37.2 Non-randomi	zed study								
Munos 1993	72	25.4	11	68.8	24.3	11	2.1%	3.20 [-17.57, 23.97]	
Prella 2002	41.6	12.6	10	40	12.6	10	6.3%	1.60 [-9.44, 12.64]	
Razek 2007	68	22.3	50	80.4	10.7	50	12.5%	-12.40 [-19.26, -5.54]	
Yang 2007	25.7	8.9	12	26.4	9.7	12	11.3%	-0.70 [-8.15, 6.75]	
Zavala 1998	45.9	16.4	8	49.3	14.1	8	3.7%	-3.40 [-18.39, 11.59]	
Subtotal (95% CI)			91			91	35.9%	-3.80 [-10.41, 2.81]	
Heterogeneity: Tau ² =	25.67; Chi ²	² = 7.77,	df = 4 (F	P = 0.10); ² = 4	19%			
Test for overall effect:	Z = 1.13 (F	P = 0.26)							
Total (95% CI)			190			189	100.0%	-0.93 [-4.01, 2.15]	-
Heterogeneity: Tau ² =	7.52; Chi ²	= 14.04,	df = 8 (F	P = 0.08); ² = 4	13%			
Test for overall effect:	Z = 0.59 (F	P = 0.56							-20 -10 0 10 20
Test for subgroup diffe	rences: Ch	$hi^2 = 1.47$	df = 1	P = 0.2	3) I ² =	32.0%			Favours VC-Civiv Favours PC-CIVIV and PC-IR

Figure 7 – Respiratory system compliance. df = degree of freedom; IV = inverse variation; PC-IRV = pressure control-inverse ratio ventilation. See Figure 4 legend for expansion of other abbreviations.

pressure.⁴² A study from Chatmongkolchart et al⁴⁸ demonstrated that a slow rise time delayed pressure delivery and increased trigger pressure-time product.

Thus, the pressure rise time in PC-CMV can sometimes be used as a method to enhance patient-ventilator synchronization.

Materials and Methods

Methodology of the Literature Search

We present a systematic review and meta-analysis comparing the physiologic effects as well as the clinical outcomes between pressure-targeted modes limiting to PC-CMV and PC-IRV and VC-CMV.

Literature Search Strategy and Trial Identification

We conducted a search of Medical Literature Analysis and Retrieval System Online (MEDLINE; 1948 to January 2014), Excerpta Medica dataBASE (EMBASE; 1980 to January 2014), and the Cochrane Central Register of Controlled Trials (CENTRAL) databases. Details of our search strategy are given in e-Appendix 1.

Eligibility Criteria

All study designs reporting the effect of PC-CMV or PC-IRV to VC-CMV during ARF were considered. Studies were considered suit-

able if they met the following criteria: (1) patients were > 18 years of age, admitted to an ICU or critical care setting, (2) patients were receiving invasive mechanical ventilation for ARF, and (3) the study reported on respiratory system compliance (Crs), gas exchange, hemodynamics, work of breathing, or clinical outcomes. We excluded studies concerning intraoperative ventilation, as we considered this a different population, as well as studies using APRV, which has different working principles.

Data Extraction and Study Quality Assessment

Two independent reviewers (N. R., C. M. K.) abstracted data and assessed study quality using the full text publications of studies. Disagreements on data abstraction were resolved by consensus and authors were contacted for additional information as needed.

To assess risk of bias for all studies, we used the Cochrane tool for risk of bias.⁴⁹ For each included trial, we categorized it as "low," "high," or



Figure 8 – A, B, Gas exchange: P/F(A) and $Paco_2(B)$. $P/F = Pao_2$ to FIO, ratio. See Figure 4 and 7 legends for expansion of other abbreviations.

"unclear" risk of bias for the following items: sequence generation, allocation concealment, adequate blinding procedures, incomplete outcome data, and selective outcome criteria for parallel-group randomized controlled trials. We report the results by type of studies.

As an additional measure of quality, we established rules for physiologic quality assessment (e-Appendix 1) to make comparisons between modes reliable and interpretable. Studies not meeting these criteria were not retained in the analysis.

Study Outcome

We compared several physiologic outcomes including Crs, gas exchange (Pao_2 to Fio_2 [P:F] ratio, $Paco_2$, and oxygenation index), hemodynamic

parameters (mean arterial pressure and cardiac index), and patient work of breathing. Clinical outcomes (ICU mortality and ICU length of stay) were also analyzed.

Statistical Analysis

Mean Difference

Data analyses were completed with RevMan5 using random effects models. The *I*² statistic documents statistical heterogeneity of effect sizes in the overall aggregations. An *I*² of <25% indicates low heterogeneity, and *I*² exceeding 75% indicates high heterogeneity. We prespecified an *I*² statistic of >50% and *P*<.05 as considerable heterogeneity between included studies. Pooled analyses included trial using PC-CMV, PC-IRV, or both in comparison with VC-CMV. Subgroup analyses are described in e-Appendix 1.

Mean Difference

A Mean arterial pressure PC-CMV and PC-IRV VC-CMV Study or Subgroup Mean SD Total Mean SD

Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
23.40.1 Randomized	study								
Auler-I 1995	83.2	9.8	10	83.4	11.9	10	5.5%	-0 20 [-9 75 9 35]	
Auler-II 1995	73.6	10.6	10	75.5	12.8	10	4 7%	-1 90 [-12 20 8 40]	
Davis 1996	81	18	25	79	14.5	50	7.6%	2 00 [-6 12 10 12]	
Lessard 1994	69	03	18	72	10	<u> </u>	8 2%	-3.00 [-10.82 4.82]	
Moreat 1993	79	0.0	20	83	12.6	10	6.5%	-5.00 [-10.02, 4.02]	
Vellvordu 1995	76	9.2	20	71	12.0	10	6.5% 5.2%	-5.00 [-15.79, 5.79]	
Subtotal (95% CI)	74	10	91	/1	10	97	37.8%	-0.96 [-4.61 2.68]	
	0.00. Chi2.	- 2 27 4		- 0.04)	12 - 00	, 3 1	57.070	-0.00 [-4.01, 2.00]	
Test for overall effect:	Z = 0.52 (P	= 2.27, di ? = 0.61)	= 5 (P	= 0.01);	1- = 0	/0			
23.40.2 Non-randomi	ized study								
Abraham 1990	77	12.6	10	75	12.6	10	4.1%	2.00 [-9.04, 13.04]	
Armstrong 1995	75	9	14	74	13	14	7.3%	1.00 [-7.28, 9.28]	
Othman 2013	94	7.7	15	91	5.5	15	21.9%	3.00 [-1.79, 7.79]	
Yang 2004	81.1	10.3	20	79.7	10.3	20	12.3%	1.40 [-4.98, 7.78]	
Yang 2007	86.5	15	12	86	12	12	4.3%	0.50 [-10.37, 11.37]	
Zavala 1998	76.1	8.2	8	73.4	4.3	8	12.2%	2.70 [-3.72, 9.12]	
Subtotal (95% CI)			79			79	62.2%	2.15 [-0.69, 4.99]	
Heterogeneity: Tau ² = Test for overall effect:	0.00; Chi² = Z = 1.48 (P	= 0.37, di 9 = 0.14)	f = 5 (P	= 1.00);	l² = 0º	%			
Total (95% CI)			170			176	100.0%	0.97 [-1.27, 3.22]	•
Heterogeneity: Tau ² =	0.00; Chi ² =	= 4.37, di	f = 11 (F	e = 0.96); ² = ()%			
T	7 - 0 95 (D	= 0.39	•						-20 -10 0 10 20
l est for overall effect:	Z - 0.03 (F	0.007							Eavours VL-LWV Eavours PL-LWV and PL-IBV
Test for subgroup diffe	erences: Ch	i ² = 1.74.	df = 1 (P = 0.1	9), l² =	42.5%			
Test for subgroup diffe	erences: Ch	i ² = 1.74,	df = 1 (P = 0.1	9), I² =	42.5%			
Test for subgroup diffe	erences: Ch	ii ² = 1.74,	df = 1 (P = 0.1	9), I² =	42.5%			
Test for subgroup diffe	erences: Ch	i ² = 1.74,	df = 1 (P = 0.1	9), l ² =	42.5%		Maan Difference	
B Cardiac inc	ilex PC-CMV	/ and PC	df = 1 (-IRV	P = 0.1	9), I ² =	42.5%	Weight	Mean Difference	Mean Difference
B Cardiac inc	dex PC-CMV Mean	i ² = 1.74, and PC	df = 1 (-IRV Total	P = 0.1 VC <u>Mean</u>	9), I ² = C-CMV SD	42.5% Total	Weight	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% Cl
B Cardiac inc Study or Subgroup 23.41.1 Randomized	dex PC-CMV Mean study	i ² = 1.74, and PC SD	df = 1 (-IRV <u>Total</u>	P = 0.1 VC <u>Mean</u>	9), I ² = C-CMV SD	42.5%	Weight	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% Cl
B Cardiac inc Study or Subgroup 23.41.1 Randomized Auler-1 1995	lex PC-CMV Mean 3.75	(and PC SD 0.71	df = 1 (-IRV <u>Total</u> 10	P = 0.1 VC <u>Mean</u> 3.44	9), I ² = C-CMV SD	42.5% Total 10	Weight 15.3%	Mean Difference IV, Random, 95% CI 0.31 [-0.27, 0.89]	Mean Difference IV, Random, 95% Cl
B Cardiac inc Study or Subgroup 23.41.1 Randomized a Auler-1 1995 Auler-11 1995	Iex PC-CMV Mean Study 3.75 2.4	0.71 0.27	df = 1 (-IRV <u>Total</u> 10	P = 0.1 VC <u>Mean</u> 3.44 2.2	9), I ² = C-CMV SD 0.61 0.25	42.5% Total 10 10	Weight 15.3% 25.8%	Mean Difference IV, Random, 95% CI 0.31 [-0.27, 0.89] 0.20 [-0.03, 0.43]	Mean Difference IV, Random, 95% Cl
B Cardiac inc Study or Subgroup 23.41.1 Randomized : Auler-1 1995 Auler-II 1995 Davis 1996	2 - 0.83 (P erences: Ch dex PC-CMV Mean study 3.75 2.4 4.7	⁷ and PC SD 0.71 0.27 1.6	df = 1 (-IRV Total 10 25	P = 0.1 VC <u>Mean</u> 3.44 2.2 4.85	9), I ² = C-CMV SD 0.61 0.25 1.3	42.5% <u>Total</u> 10 10 50	Weight 15.3% 25.8% 12.0%	Mean Difference IV, Random, 95% CI 0.31 [-0.27, 0.89] 0.20 [-0.03, 0.43] -0.15 [-0.87, 0.57]	Mean Difference IV, Random, 95% Cl
B Cardiac inc Study or Subgroup 23.41.1 Randomized = Auler-1 1995 Davis 1996 Lessard 1994	2 - 0.83 (P erences: Ch dean study 3.75 2.4 4.7 4.4	0.27 0.27 0.27 1.6 1.6	df = 1 (-IRV Total 10 25 18	P = 0.1 VC <u>Mean</u> 3.44 2.2 4.85 4.4	9), I ² = C-CMV SD 0.61 0.25 1.3 1.5	42.5% <u>Total</u> 10 10 50 9	Weight 15.3% 25.8% 12.0% 5.7%	Mean Difference IV, Random, 95% CI 0.31 [-0.27, 0.89] 0.20 [-0.03, 0.43] -0.15 [-0.87, 0.57] 0.00 [-1.23, 1.23]	Mean Difference IV, Random, 95% Cl
B Cardiac inc Study or Subgroup 23.41.1 Randomized a Auler-I 1995 Auler-I 1996 Lessard 1994 Mercat 1993	2 - 0.83 (P erences: Ch dex PC-CMV Mean study 3.75 2.4 4.7 4.4 3.45	0.71 0.71 0.27 1.6 1.6 0.6	df = 1 (-IRV Total 10 25 18 20	P = 0.1 VC <u>Mean</u> 3.44 2.2 4.85 4.4 3.7	9), I ² = C-CMV SD 0.61 0.25 1.3 1.5 0.6	42.5% <u>Total</u> 10 10 50 9 10	Weight 15.3% 25.8% 12.0% 5.7% 18.7%	Mean Difference IV, Random, 95% CI 0.31 [-0.27, 0.89] 0.20 [-0.03, 0.43] -0.15 [-0.87, 0.57] 0.00 [-1.23, 1.23] -0.25 [-0.71, 0.21]	Mean Difference IV, Random, 95% Cl
B Cardiac inc Study or Subgroup 23.41.1 Randomized : Auler-I 1995 Auler-II 1995 Lessard 1994 Mercat 1993 Subtotal (95% CI)	2 - 0.83 (Perences: Ch dex PC-CMV Mean study 3.75 2.4 4.7 4.7 4.4 3.45	0.71 0.71 0.27 1.6 0.6	df = 1 (-IRV Total 10 25 18 20 83	P = 0.1 VC <u>Mean</u> 3.44 2.2 4.85 4.4 3.7	9), I ² = C-CMV SD 0.61 0.25 1.3 1.5 0.6	42.5% Total 10 10 50 9 10 89	Weight 15.3% 25.8% 12.0% 5.7% 18.7% 77.6%	Mean Difference IV, Random, 95% CI 0.31 [-0.27, 0.89] 0.20 [-0.03, 0.43] -0.15 [-0.87, 0.57] 0.00 [-1.23, 1.23] -0.25 [-0.71, 0.21] 0.11 [-0.07, 0.29]	Mean Difference IV, Random, 95% Cl
B Cardiac inc Study or Subgroup 23.41.1 Randomized : Auler-1 1995 Auler-11 1995 Davis 1996 Lessard 1994 Mercat 1993 Subtotal (95% Cl) Heterogeneity: Tau ² =	2 - 0.03 (P erences: Ch dex PC-CMV Mean 3.75 2.4 4.7 4.4 3.45 0.00; Chi ² =	0.71 0.71 0.27 1.6 1.6 0.6	df = 1 (-IRV Total 10 10 25 18 20 83 = 4 (P =	P = 0.1 VC <u>Mean</u> 3.44 2.2 4.85 4.4 3.7 = 0.41);	9), I ² = C-CMV SD 0.61 0.25 1.3 1.5 0.6 I ² = 09	42.5% <u>Total</u> 10 50 9 10 89 6	Weight 15.3% 25.8% 12.0% 5.7% 18.7% 77.6%	Mean Difference IV, Random, 95% CI 0.31 [-0.27, 0.89] 0.20 [-0.03, 0.43] -0.15 [-0.87, 0.57] 0.00 [-1.23, 1.23] -0.25 [-0.71, 0.21] 0.11 [-0.07, 0.29]	Mean Difference IV, Random, 95% Cl
B Cardiac inc Study or Subgroup 23.41.1 Randomized : Auler-1 1995 Auler-1 1995 Davis 1996 Lessard 1994 Mercat 1993 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect:	2 - 0.83 (P erences: Ch erences: Ch Study 3.75 2.4 4.7 4.4 3.45 0.00; Chi ² = Z = 1.18 (P	0.71 0.71 0.27 1.6 1.6 0.6 = 3.98, df = 0.24)	df = 1 (-IRV Total 10 25 18 20 83 = 4 (P =	P = 0.1 VC <u>Mean</u> 3.44 2.2 4.85 4.4 3.7 = 0.41);	9), I ² = C-CMV SD 0.61 0.25 1.3 1.5 0.6 I ² = 09	42.5% <u>Total</u> 10 10 50 9 10 89 %	Weight 15.3% 25.8% 12.0% 5.7% 18.7% 77.6%	Mean Difference IV, Random, 95% CI 0.31 [-0.27, 0.89] 0.20 [-0.03, 0.43] -0.15 [-0.87, 0.57] 0.00 [-1.23, 1.23] -0.25 [-0.71, 0.21] 0.11 [-0.07, 0.29]	Mean Difference IV, Random, 95% Cl
B Cardiac inc Study or Subgroup 23.41.1 Randomized i Auler-I 1995 Auler-I 1995 Davis 1996 Lessard 1994 Mercat 1993 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 23.41.2 Non-randomized	2 = 0.83 (P erences: Ch dex PC-CMV Mean study 3.75 2.4 4.7 4.4 3.45 0.00; Chi ² = Z = 1.18 (P zed study	² and PC <u>SD</u> 0.71 0.27 1.6 1.6 0.6 = 3.98, df = 0.24)	df = 1 (-IRV Total 10 25 18 20 83 = 4 (P =	VC Mean 3.44 2.2 4.85 4.4 3.7 = 0.41);	9), I ² = C-CMV SD 0.61 0.25 1.3 1.5 0.6 I ² = 09	42.5% <u>Total</u> 10 10 50 9 10 89 %	Weight 15.3% 25.8% 12.0% 5.7% 18.7% 77.6%	Mean Difference IV, Random, 95% CI 0.31 [-0.27, 0.89] 0.20 [-0.03, 0.43] -0.15 [-0.87, 0.57] 0.00 [-1.23, 1.23] -0.25 [-0.71, 0.21] 0.11 [-0.07, 0.29]	Mean Difference IV, Random, 95% Cl
B Cardiac inc Study or Subgroup 23.41.1 Randomized : Auler-1 1995 Auler-1 1995 Davis 1996 Lessard 1994 Mercat 1993 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect : 23.41.2 Non-randomiz Abraham 1990	2 - 0.83 (P erences: Ch dex PC-CMV Mean study 3.75 2.4 4.7 4.4 3.45 0.00; Chi ² = Z = 1.18 (P zed study 4.1	² and PC <u>SD</u> 0.71 0.27 1.6 1.6 0.6 = 3.98, df = 0.24) 1.3	df = 1 (-IRV Total 10 25 18 20 83 = 4 (P =	P = 0.1 VC <u>Mean</u> 3.44 2.2 4.85 4.4 3.7 = 0.41); 3.9	9), I ² = C-CMV SD 0.61 0.25 1.3 1.5 0.6 I ² = 0% 1.6	42.5% <u>Total</u> 10 10 50 9 10 89 %	Weight 15.3% 25.8% 12.0% 5.7% 18.7% 77.6%	Mean Difference IV, Random, 95% CI 0.31 [-0.27, 0.89] 0.20 [-0.03, 0.43] -0.15 [-0.87, 0.57] 0.00 [-1.23, 1.23] -0.25 [-0.71, 0.21] 0.11 [-0.07, 0.29] 0.20 [-1.08, 1.48]	Mean Difference IV, Random, 95% Cl
Test for overall effect: Test for subgroup diffe B Cardiac incomplete 23.41.1 Randomized : Auler-1 1995 Davis 1996 Lessard 1994 Mercat 1993 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 23.41.2 Non-randomi: Abraham 1990 Armstrong 1995	2 - 0.83 (P erences: Ch lex PC-CMV Mean 3.75 2.4 4.7 4.4 3.45 0.00; Chi ² = Z = 1.18 (P zed study 4.1 2.8	2 and PC 5D 0.71 0.27 1.6 1.6 0.6 3.98, df = 0.24) 1.3 0.8	df = 1 (-IRV <u>Total</u> 10 25 18 20 83 = 4 (P = 10 14	P = 0.1 VC <u>Mean</u> 3.44 2.2 4.85 4.4 3.7 = 0.41); 3.9 3.81	9), ² = C-CMV SD 0.61 0.25 1.3 1.5 0.6 ² = 09 1.6 1.1	42.5% Total 10 10 50 9 10 89 6 10 10 11 10 10 10 10 10 10 10	Weight 15.3% 25.8% 12.0% 5.7% 18.7% 77.6%	Mean Difference IV, Random, 95% CI 0.31 [-0.27, 0.89] 0.20 [-0.03, 0.43] -0.15 [-0.87, 0.57] 0.00 [-1.23, 1.23] -0.25 [-0.71, 0.21] 0.11 [-0.07, 0.29] 0.20 [-1.08, 1.48] -1.01 [-1.72, -0.30]	Mean Difference IV, Random, 95% CI
B Cardiac inc Study or Subgroup 23.41.1 Randomized : Auler-1 1995 Auler-1 1995 Davis 1996 Lessard 1994 Mercat 1993 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect : 23.41.2 Non-randomiz Abraham 1990 Armstrong 1995 Poelaert 1993 Subtotal (95% CI)	2 - 0.83 (Perences: Ch 2 - 0.83 (PC-CMV Mean study 3.75 2.4 4.7 4.4 3.45 0.00; Chi ² = Z = 1.18 (P zed study 4.1 2.8 5.56	2 and PC SD 0.71 0.27 1.6 1.6 0.6 = 3.98, df = 0.24) 1.3 0.8 1.66	df = 1 (-IRV Total 10 10 25 18 20 83 = 4 (P = 10 14 12 36	VC Mean 3.44 2.2 4.85 4.4 3.7 = 0.41); 3.9 3.81 4.73	9), ² = C-CMV SD 0.61 1.3 1.5 0.6 ² = 09 1.6 1.1 1.71	42.5% Total 10 10 50 9 10 89 6 10 14 12 36 36	Weight 15.3% 25.8% 12.0% 5.7% 18.7% 77.6% 5.3% 12.2% 4.9% 22.4%	Mean Difference IV, Random, 95% CI 0.31 [-0.27, 0.89] 0.20 [-0.03, 0.43] -0.15 [-0.87, 0.57] 0.00 [-1.23, 1.23] -0.25 [-0.71, 0.21] 0.11 [-0.07, 0.29] 0.20 [-1.08, 1.48] -1.01 [-1.72, -0.30] 0.83 [-0.52, 2.18] -0.11 [-1.28, 1.06]	Mean Difference IV, Random, 95% Cl
Test for overall effect: Test for subgroup diffe B Cardiac incomplete Study or Subgroup 23.41.1 Randomized : Auler-1 1995 Davis 1996 Lessard 1994 Mercat 1993 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 23.41.2 Non-randomi: Abraham 1990 Armstrong 1995 Poelaert 1993 Subtotal (95% Cl)	2 - 0.83 (F erences: Ch lex PC-CMV Mean 3.75 2.4 4.7 4.4 3.45 0.00; Chi ² = Z = 1.18 (P zed study 4.1 2.8 5.56 0.75; Chi ² =	(and PC SD 0.71 0.27 1.6 1.6 0.6 = 3.98, df = 0.24) 1.3 0.8 1.66 = 6.83, df	df = 1 (-IRV Total 10 10 25 18 20 83 = 4 (P = 10 14 12 36 = 2 (P =	VC Mean 3.44 2.2 4.85 4.4 3.7 = 0.41); 3.9 3.81 4.73 = 0.03);	9), ² = C-CMV SD 0.61 0.25 1.3 1.5 0.6 ² = 0 ⁹ 1.6 1.1 1.71 ² = 71	42.5% Total 10 10 50 9 10 89 6 10 14 12 36 %	Weight 15.3% 25.8% 12.0% 5.7% 18.7% 77.6% 5.3% 12.2% 4.9% 22.4%	Mean Difference IV, Random, 95% CI 0.31 [-0.27, 0.89] 0.20 [-0.03, 0.43] -0.15 [-0.87, 0.57] 0.00 [-1.23, 1.23] -0.25 [-0.71, 0.21] 0.11 [-0.07, 0.29] 0.20 [-1.08, 1.48] -1.01 [-1.72, -0.30] 0.83 [-0.52, 2.18] -0.11 [-1.28, 1.06]	Mean Difference IV, Random, 95% CI
B Cardiac inc Study or Subgroup 23.41.1 Randomized : Auler-I 1995 Auler-I 1995 Auler-II 1995 Davis 1996 Lessard 1994 Mercat 1993 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 23.41.2 Non-randomix Abraham 1990 Armstrong 1995 Poelaert 1993 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect:	$\begin{array}{c} \textbf{J} = 0.83 \ (Perences: Ch) \\ \textbf{J} ex \\ \textbf{Mean} \\ \textbf{study} \\ 3.75 \\ 2.4 \\ 4.7 \\ 4.4 \\ 3.45 \\ 0.00; Chi2 = \\ Z = 1.18 \ (P \\ \textbf{zet study} \\ 4.1 \\ 2.8 \\ 5.56 \\ 0.75; Chi2 = \\ Z = 0.18 \ (P \\ \textbf{zet study} \\ $	<pre>/ and PC SD 0.71 0.27 1.6 0.6 = 3.98, df = 0.24) 1.3 0.8 1.66 = 6.83, df = 0.86)</pre>	df = 1 (-IRV <u>Total</u> 10 10 25 18 20 83 20 83 21 10 10 10 10 25 18 20 83 21 21 21 21 21 21 21 21 21 21	P = 0.1 VC Mean 3.44 2.2 4.85 4.4 3.7 = 0.41); 3.9 3.81 4.73 3.81 4.73	9), I ² = SD 0.61 0.25 1.3 1.5 0.6 I ² = 09 1.6 1.1 1.71 I ² = 71	42.5% Total 10 10 50 9 10 89 6 10 14 12 36 %	Weight 15.3% 25.8% 12.0% 5.7% 18.7% 77.6% 5.3% 12.2% 4.9% 22.4%	Mean Difference IV, Random, 95% CI 0.31 [-0.27, 0.89] 0.20 [-0.03, 0.43] -0.15 [-0.87, 0.57] 0.00 [-1.23, 1.23] -0.25 [-0.71, 0.21] 0.11 [-0.07, 0.29] 0.20 [-1.08, 1.48] -1.01 [-1.72, -0.30] 0.83 [-0.52, 2.18] -0.11 [-1.28, 1.06]	Mean Difference IV, Random, 95% Cl
B Cardiac inc Study or Subgroup 23.41.1 Randomized : Auler-I 1995 Auler-I 1995 Auler-I 1995 Davis 1996 Lessard 1994 Mercat 1993 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 23.41.2 Non-randomix Abraham 1990 Armstrong 1995 Poelaert 1993 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Total (95% Cl)	$\begin{array}{c} \textbf{J} = 0.83 \ (Perences: Ch) \\ \textbf{Jex} \\ \textbf{Mean} \\ \textbf{study} \\ 3.75 \\ 2.4 \\ 4.7 \\ 4.4 \\ 3.45 \\ 0.00; Chi2 = \\ Z = 1.18 \ (P \\ \textbf{zet study} \\ 4.1 \\ 2.8 \\ 5.56 \\ 0.75; Chi2 = \\ Z = 0.18 \ (P \\ \textbf{zet study} \\ \textbf$	<pre>/ and PC SD 0.71 0.27 1.6 0.6 = 3.98, df = 0.24) 1.3 0.8 1.66 1.66 = 6.83, df = 0.86)</pre>	df = 1 (-IRV <u>Total</u> 10 10 25 18 20 83 20 83 21 10 10 10 25 18 20 83 20 83 20 83 20 83 20 83 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 25 20 25 25 25 25 25 25 25 25 20 25 25 25 25 25 25 25 25 25 25	P = 0.1 VC Mean 3.44 2.2 4.85 4.4 3.7 = 0.41); 3.81 4.73 3.81 4.73	9), ² = SD 0.61 0.25 1.3 1.5 0.6 ² = 0 ⁹ 1.6 1.1 1.71 ² = 71	42.5% Total 10 10 50 9 10 89 6 10 14 12 36 % 125	Weight 15.3% 25.8% 12.0% 5.7% 18.7% 77.6% 5.3% 12.2% 4.9% 22.4%	Mean Difference IV, Random, 95% CI 0.31 [-0.27, 0.89] 0.20 [-0.03, 0.43] -0.15 [-0.87, 0.57] 0.00 [-1.23, 1.23] -0.25 [-0.71, 0.21] 0.11 [-0.07, 0.29] 0.20 [-1.08, 1.48] -1.01 [-1.72, -0.30] 0.83 [-0.52, 2.18] -0.11 [-1.28, 1.06] -0.04 [-0.36, 0.29]	Mean Difference IV, Random, 95% Cl
B Cardiac inc Study or Subgroup 23.41.1 Randomized : Auler-I 1995 Auler-I 1995 Auler-II 1995 Davis 1996 Lessard 1994 Mercat 1993 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 23.41.2 Non-randomiz Abraham 1990 Armstrong 1995 Poelaert 1993 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: Total (95% CI) Heterogeneity: Tau ² =	$\begin{array}{c} \textbf{J} = 0.85 \ (F) \\ \textbf{e}rences: Ch \\ \textbf{Jex} \\ \textbf{Mean} \\ \textbf{study} \\ \textbf{3.75} \\ \textbf{2.4} \\ \textbf{4.7} \\ \textbf{4.4} \\ \textbf{3.45} \\ \textbf{0.00; Chi^2} = \\ \textbf{Z} = 1.18 \ (P) \\ \textbf{zed study} \\ \textbf{4.1} \\ \textbf{2.8} \\ \textbf{5.56} \\ \textbf{0.75; Chi^2} = \\ \textbf{Z} = 0.18 \ (P) \\ \textbf{0.09; Chi^2} = \\$	2 and PC SD 0.71 0.27 1.6 1.6 0.6 = 3.98, df = 0.24) 1.3 0.8 1.66 = 6.83, df = 0.86) = 14.24, c	df = 1 (-IRV <u>Total</u> 10 10 25 18 20 83 20 83 21 18 20 83 21 20 83 21 20 83 21 20 83 21 20 10 10 25 18 20 83 20 83 21 10 10 10 25 18 20 83 20 10 10 10 25 18 20 83 20 83 21 10 10 10 25 18 20 83 20 10 10 10 25 18 20 83 20 83 20 10 10 10 10 10 25 18 20 83 26 10 10 10 10 10 10 10 10 10 10	P = 0.1 VC Mean 3.44 2.2 4.85 4.4 3.7 5.81 4.73 3.9 3.81 4.73 3.9 3.81 4.73 2.5 2.5 4.4 5.5 4.4 5.5 4.4 5.5 4.4 5.5 5.5	9), $ ^2 = 5$ SD 0.61 0.25 1.3 1.5 0.6 1.1 1.71 $ ^2 = 0^9$ 1.6 1.71 $ ^2 = 71$ $ ^2 = 71$ $ ^2 = 5$	42.5% Total 10 10 50 9 10 89 6 10 14 125 36 % 125 1%	Weight 15.3% 25.8% 12.0% 5.7% 18.7% 77.6% 5.3% 12.2% 4.9% 22.4% 100.0%	Mean Difference IV, Random, 95% CI 0.31 [-0.27, 0.89] 0.20 [-0.03, 0.43] -0.15 [-0.87, 0.57] 0.00 [-1.23, 1.23] -0.25 [-0.71, 0.21] 0.11 [-0.07, 0.29] 0.20 [-1.08, 1.48] -1.01 [-1.72, -0.30] 0.83 [-0.52, 2.18] -0.11 [-1.28, 1.06] -0.04 [-0.36, 0.29]	Mean Difference IV, Random, 95% CI

Figure 9 – A, B, Hemodynamic parameters: mean arterial pressure (A) and cardiac index (B). See Figure 4 and 7 legends for expansion of abbreviations.

Test for subgroup differences: $Chi^2 = 0.13$, df = 1 (P = 0.72), $I^2 = 0\%$

Results

Using MEDLINE and EMBASE, 1,288 titles and abstracts were identified in the primary search. The CENTRAL database yielded 651 titles and abstracts in primary review. After elimination of duplicates, 815 articles remained (Fig 6). The characteristics of each trial are documented in Table 1.^{10,32,39-41,44-47,50-74} In total, 880 patients from 34 studies were included, all having ARF, representing diverse medical and surgical populations. In total, 407 patients (46.2%) were documented as fulfilling ARDS criteria. Summaries of specific selection criteria, trial characteristics, and quality assessment are detailed in e-Appendix 1.

Outcomes

Respiratory System Mechanics: From the pooled analysis of PC-CMV and PC-IRV, no significant difference in Crs was found between modes (nine studies, n = 379 patients, mean difference of -0.9 mL/cm H₂O; 95% CI, -4.0, 2.2) (Fig 7). The same result was observed in the subgroups of PC-CMV, PC-IRV, ARDS, and non-ARDS (e-Fig 1).

Gas Exchange: P:F ratio in PC-CMV/PC-IRV was similar to VC-CMV (n = 120) with a mean difference of 11.2 mm Hg (95% CI, -11.1, 33.5) and no statistical significance (Fig 8A). This result was also consistent in subgroups of PC-CMV and PC-IRV, and in ARDS (e-Fig 2). No significant difference in Paco₂ was found between PC-CMV/PC-IRV and VC-CMV (Fig 8B) and also in the subgroups of PC-CMV, PC-IRV, and ARDS (e-Fig 3). For oxygenation index (a lower oxygenation index is more favorable), we included only three PC-IRV studies,^{55,61,69} with 60 patients. The mean difference between PC-IRV and VC-CMV studies was 4.2 cm H₂O/mm Hg (95% CI, -0.8, 9.1), in favor of VC-CMV, but was nonsignificant (e-Fig 4).

Hemodynamic Parameters: There was no difference between PC-CMV/PC-IRV and VC-CMV regarding mean arterial pressure (346 patients) or cardiac index (244 patient) (Fig 9). Subgroup analysis of PC-CMV, PC-IRV, ARDS, and non-ARDS showed no difference between modes (e-Figs 5, 6).

Work of Breathing: We included five studies for work of breathing (n = 124). In pooled study, there was no significant difference between modes. In subgroup analysis, PCV showed a significant reduction of patient work of breathing when inspiratory flow rate was insufficient in VC-CMV, with a mean difference of -0.34 Joules/L (95% CI, -0.63, -0.04). However,

PC-CMV did not demonstrate any benefit when inspiratory flow rate was the same as in VC-CMV (Fig 10).

Clinical Outcomes: No difference in ICU mortality (n = 221) was found between PC-CMV and VC-CMV. There was also no significant difference in ICU length of stay (n = 194) between the two modes (Fig 11).

Discussion

We could not demonstrate any systematic difference between PC-CMV or PC-IRV vs VC-CMV in terms of physiologic (Crs, gas exchange, and hemodynamics) or clinical outcomes (ICU mortality and length of stay). PC-CMV has a benefit in reducing patient work of breathing only when inspiratory flow rate is insufficiently set in VC-CMV. As previously discussed, this does not mean that the two modes are equivalent. The choice of the mode of ventilation in patients should be based on clinical context and individual adjustment of the setting by considering the important factors such as diagnosis, pattern of breathing (passive or active respiration), and patient-ventilator synchrony and on the clinician's priorities for the patient, such as lung protection vs comfort.

From a physiologic standpoint, PC-CMV could theoretically provide a different gas distribution than VC-CMV due to a decelerating flow pattern. However, we could not find any difference in P:F ratio between two modes. The calculated oxygenation index, if any different, tended to be worse with PC-IRV than VC-CMV. We think that these possible differences in ventilation distribution have probably no or very marginal consequences on gas exchange in most patients, provided the VT is the same than in VC-CMV.

Physiologic knowledge tells us that possible differences between modes may be observed in case of acute changes in respiratory mechanics, in terms of lung protection, and regarding patient's comfort or work of breathing during assisted ("triggered") ventilation. Existing studies do not provide any data showing clinical differences but very few focused on these circumstances. Moreover, results may vary markedly with the precise settings of each of these modes, as shown by Cinnella et al.³² Given the lack of details about actual ventilatory settings for clinical studies comparing PC-CMV and VC-CMV, it is not surprising that no differences were found in clinical outcomes.

Our study has strengths and weaknesses. We included all identified trials in critically ill patients, enhancing generalizability and optimizing pragmatism. We used a

	PC	C-CMV		V	С-СМ\	/		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
23.36.1 WOB differen	it peak f	low ra	te						
Cinnella-I 1996	0.82	0.13	7	1.4	0.3	7	19.5%	-0.58 [-0.82, -0.34]	
Kallet 2000	0.59	0.42	18	0.7	0.58	18	16.4%	-0.11 [-0.44, 0.22]	
Kim 1999	0.8	0.37	10	1.06	0.39	10	16.3%	-0.26 [-0.59, 0.07]	
Subtotal (95% CI)			35			35	52.3%	-0.34 [-0.63, -0.04]	\bullet
Heterogeneity: Tau ² =	0.04; Cł	ni² = 5.0	67, df =	= 2 (P =	0.06);	l² = 65	%		
Test for overall effect:	Z = 2.25	6 (P = C	0.02)						
23.36.2 WOB same p	eak flow	/ rate							
Chiumello 2003	0.5	0.49	7	0.33	0.3	7	13.4%	0.17 [-0.26, 0.60]	-+
Cinnella-II 1996	0.31	0.15	6	0.42	0.19	6	21.2%	-0.11 [-0.30, 0.08]	
Kallet 2005	1.27	0.58	14	1.09	0.59	14	13.1%	0.18 [-0.25, 0.61]	-+
Subtotal (95% CI)			27			27	47.7%	-0.00 [-0.20, 0.19]	•
Heterogeneity: Tau ² =	0.01; Cł	ni² = 2.4	40, df =	= 2 (P =	0.30);	l² = 17	%		
Test for overall effect:	Z = 0.04	(P = 0	.97)						
Total (95% CI)			62			62	100.0%	-0.15 [-0.38, 0.08]	•
Heterogeneity: Tau ² =	0.05; Cł	ni² = 16	5.55, df	= 5 (P	= 0.00	5); l² =	70%	H	
Test for overall effect:	Z = 1.30	(P = 0).19)						
Test for subgroup diffe	rences.	Chi ² =	340	lf = 1 (P	P = 0 0	7) l ² =	70.6%		Favours PC-Civix Favours VC-CIVIV

Figure 10 - Patient work of breathing. WOB = work of breathing. See Figure 4 and 7 legends for expansion of other abbreviations.

rigorous methodologic and physiologic quality assessment. Our results, however, show that many of the trials included are small, varying in study designs, with high heterogeneity in terms of quality. Physiologic quality assessment for inclusion into a meta-analysis has not been previously described. When including physiologic studies in meta-analysis, we believe that selecting the studies based on minimal physiologic requirements is necessary to make the aggregation of studies more meaningful and, therefore, to improve the overall quality of the analysis. To our knowledge, this study is also the first formal meta-analysis comparing these modes of ventilation regarding physiologic and clinical outcomes and using a physiologic approach for the selection of studies and the comparison of the outcomes.

Conclusions

In summary, this narrative review and meta-analysis provides a comprehensive, rigorous, and exhaustive inclusion of studies comparing PC-CMV and PC-IRV

A ICU mortality									
	PC	см	,	VC-C	мv			Odds Ratio	Odds Ratio
Study or Subgroup	Even	ts T	otal	Events	Tota	l We	ight I	I-H, Random, 95% Cl	M-H, Random, 95% Cl
Esteban 2000	1	8	37	29	43	2 34	.1%	0.42 [0.17, 1.06]	
Gritsan 2012		8	36	4	39	9 25	5.3%	2.50 [0.68, 9.16]	
Karakurt 2009		5	20	3	20	20).2%	1.89 [0.38, 9.27]	
Rappaport 1994		9	16	7	1	1 20).4%	0.73 [0.15, 3.55]	
Total (95% CI)			109		112	2 100	0.0%	1.01 [0.40, 2.51]	-
Total events	4	0		43					
Heterogeneity: Tau ² =	0.42; C	hi² =	5.84,	df = 3 (F	• = 0.*	12); l²	= 49%		
Test for overall effect:	Z = 0.0	1 (P	= 0.99))				0.01	Eavours PC-CMV Eavours VC-CMV
B ICU length of st	ay								
	PC	-CM\	/	vo	-CMV			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weigh	t IV, Random, 95% CI	IV, Random, 95% Cl
Esteban 2000	21	15	37	25	19	42	24.1%	-4.00 [-11.51, 3.51]	
Gritson 2012									
Ontsan 2012	12.8	6	36	18.7	14.8	39	36.5%	-5.90 [-10.94, -0.86]	
Karakurt 2009	12.8 11	6 7.4	36 20	18.7 9.9	14.8 7.4	39 20	36.5% 39.4%	5.90 [-10.94, -0.86] 1.10 [-3.49, 5.69]	
Karakurt 2009 Total (95% CI)	12.8 11	6 7.4	36 20 93	18.7 9.9	14.8 7.4	39 20 101	36.5% 39.4% 100.0 %	 -5.90 [-10.94, -0.86] 1.10 [-3.49, 5.69] -2.69 [-7.37, 2.00] 	
Karakurt 2009 Total (95% CI) Heterogeneity: Tau ² =	12.8 11 9.03; Ch	6 7.4 i ² = 4	36 20 93 I.26, dt	18.7 9.9 f = 2 (P =	14.8 7.4 = 0.12)	39 20 101 ; I ² = 5	36.5% 39.4% 100.0% 3%	-5.90 [-10.94, -0.86] 1.10 [-3.49, 5.69] -2.69 [-7.37, 2.00]	

Figure 11 – A, B, Clinical outcomes: ICU mortality (A) and ICU length of stay (B). M-H = Mantel-Haenszel. See Figure 4 and 7 legends for expansion of other abbreviations.

to VC-CMV in critically ill patients with ARF in the context of an increasing use of pressure-targeted modes over the world. We could not find any significant differences between these modes in either physiologic or clinical outcomes, but included trials were small and varied considerably in quality. Our study may provide insights regarding the choice of ventilation of patients with ARF. Indeed, considering the working principles and the physiologic effects of the two types of breath, appropriately adjusting the ventilator settings regarding patient's individual characteristics may help to better ensure protective lung ventilation in some cases and to minimize work of breathing and improve comfort in others. We showed here that the overall outcome of ventilation will be unlikely influenced by simply using one breath type vs the other for all patients.

Acknowledgments

Author contributions: L. B. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. N. R. contributed to study conception, design, and selection, assessment of risk of bias and extraction, data analysis and interpretation, the draft of the manuscript, and critical revision and final approval of the manuscript; C. M. K. contributed to study conception and design, assessment of risk of bias and extraction, data analysis and interpretation, the draft of the manuscript, and critical revision and final approval of the manuscript; F. B. contributed to study selection, data interpretation, and critical revision and final approval of the manuscript; J. O. F. and J. M. contributed to data interpretation and critical revision and final approval of the manuscript; and L. B. contributed to the study conception and design, data interpretation, and critical revision and final approval of the manuscript.

Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Rittayamai was receiving a grant from Faculty of Medicine Siriraj Hospital, Bangkok, Thailand. Dr Beloncle was receiving a grant from Hospital of Angers, L'Université Nantes Angers Le Mans, Angers, France. Dr Mancebo has received research grants from Covidien (PAV) and General Electric (lung volume) and personal fees from Faron Pharmaceuticals and ALung Technologies, Inc. Dr Brochard's laboratory has received research grants from the following companies: Covidien (PAV), General Electric (lung volume measurement), Drägerwerk AG & Co KGaA (SmartCare), Vygon SA (CPAP), Fisher & Paykel Healthcare Limited (Optiflow). Dr Brochard has received consultant fees from Covidien and Drägerwerk AG & Co KGaA. St. Michael's Hospital is receiving royalties from MAQUET Holding BV & Co KG. Drs Katsios and Friedrich have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Other contributions: We acknowledge the help of all authors who responded to our requests and inquiries (Alexei Gritsan, MD, DSc; Ashraf EL Masry, MD; and Richard H. Kallet, MSc, RRT, FAARC). We thank those individuals who helped us translate foreign language manuscripts: Lu Chen, MD, and Hannah Park, MD.

Additional information: The e-Appendix, e-Figures, and e-Tables can be found in the Supplemental Materials section of the online article.

References

- Chatburn RL. Classification of ventilator modes: update and proposal for implementation. *Respir Care*. 2007;52(3): 301-323.
- Chatburn RL, El-Khatib M, Mireles-Cabodevila E. A taxonomy for mechanical ventilation: 10 fundamental maxims. *Respir Care*. 2014;59(11):1747-1763.
- Esteban A, Anzueto A, Frutos F, et al; Mechanical Ventilation International Study Group. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA. 2002;287(3):345-355.
- Esteban A, Ferguson ND, Meade MO, et al; VENTILA Group. Evolution of mechanical ventilation in response to clinical research. *Am J Respir Crit Care Med.* 2008;177(2):170-177.
- 5. Esteban A, Frutos-Vivar F, Muriel A, et al. Evolution of mortality over time in patients receiving mechanical ventilation. *Am J Respir Crit Care Med.* 2013;188(2):220-230.
- Burke WC, Crooke PS III, Marcy TW, Adams AB, Marini JJ. Comparison of mathematical and mechanical models of pressure-controlled ventilation. J Appl Physiol. 1993;74(2):922-933.
- Garnero AJ, Abbona H, Gordo-Vidal F, Hermosa-Gelbard C; Grupo de Insuficiencia Respiratoria Aguda de SEMICYUC. Pressure versus volume controlled modes in invasive mechanical ventilation. *Med Intensiva*. 2013;37(4): 292-298.
- Amato MBP, Marini JJ. Pressurecontrolled and inverse-ratio ventilation. In: Tobin MJ, ed. *Principles and Practice* of Mechanical Ventilation. 3rd ed. New York, NY: McGraw-Hill; 2013:227-251.
- Marik PE, Krikorian J. Pressurecontrolled ventilation in ARDS: a practical approach. *Chest.* 1997;112(4): 1102-1106.
- Esteban A, Alía I, Gordo F, et al; for the Spanish Lung Failure Collaborative Group. Prospective randomized trial

comparing pressure-controlled ventilation and volume-controlled ventilation in ARDS. *Chest.* 2000;117(6):1690-1696.

- Esan A, Hess DR, Raoof S, George L, Sessler CN. Severe hypoxemic respiratory failure: part 1—ventilatory strategies. *Chest*. 2010;137(5):1203-1216.
- Koh SO. Mode of mechanical ventilation: volume controlled mode. *Crit Care Clin.* 2007;23(2):161-167.
- MacIntyre N. Counterpoint: is pressure assist-control preferred over volume assist-control mode for lung protective ventilation in patients with ARDS? No. *Chest.* 2011;140(2):290-292.
- Mancebo J. Assist-control ventilation. In: Tobin MJ, ed. *Principles and Practice of Mechanical Ventilation*. 3rd ed. New York, NY: McGraw-Hill; 2013:159-174.
- Brochard L, Martin GS, Blanch L, et al. Clinical review: respiratory monitoring in the ICU - a consensus of 16. *Crit Care*. 2012;16(2):219.
- Lyazidi A, Thille AW, Carteaux G, Galia F, Brochard L, Richard JCM. Bench test evaluation of volume delivered by modern ICU ventilators during volumecontrolled ventilation. *Intensive Care Med.* 2010;36(12):2074-2080.
- Boussarsar M, Thierry G, Jaber S, Roudot-Thoraval F, Lemaire F, Brochard L. Relationship between ventilatory settings and barotrauma in the acute respiratory distress syndrome. *Intensive Care Med.* 2002;28(4):406-413.
- Blanch L, Bernabé F, Lucangelo U. Measurement of air trapping, intrinsic positive end-expiratory pressure, and dynamic hyperinflation in mechanically ventilated patients. *Respir Care*. 2005; 50(1):110-123.
- Laghi F. Effect of inspiratory time and flow settings during assist-control ventilation. *Curr Opin Crit Care*. 2003;9(1): 39-44.
- 20. Daoud EG, Farag HL, Chatburn RL. Airway pressure release ventilation: what do we know? *Respir Care*. 2012;57(2): 282-292.
- Lourens MS, van den Berg B, Aerts JG, Verbraak AF, Hoogsteden HC, Bogaard JM. Expiratory time constants in mechanically ventilated patients with and without COPD. *Intensive Care Med.* 2000;26(11):1612-1618.
- 22. Putensen C. Airway pressure release ventilation. In: Tobin MJ, ed. *Principles*

and Practice of Mechanical Ventilation. 3rd ed. New York, NY: McGraw-Hill; 2013:305-313.

- Marini JJ, Crooke PS III, Truwit JD. Determinants and limits of pressurepreset ventilation: a mathematical model of pressure control. *J Appl Physiol.* 1989;67(3):1081-1092.
- Chatburn RL. Understanding mechanical ventilators. *Expert Rev Respir Med.* 2010;4(6):809-819.
- Lucangelo U, Bernabè F, Blanch L. Lung mechanics at the bedside: make it simple. *Curr Opin Crit Care*. 2007;13(1):64-72.
- Nichols D, Haranath S. Pressure control ventilation. *Crit Care Clin*. 2007;23(2): 183-199.
- Yoshida T, Torsani V, Gomes S, et al. Spontaneous effort causes occult pendelluft during mechanical ventilation. *Am J Respir Crit Care Med.* 2013;188(12): 1420-1427.
- Akoumianaki E, Maggiore SM, Valenza F, et al. The application of esophageal pressure measurement in patients with respiratory failure. *Am J Respir Crit Care Med.* 2014;189(5):520-531.
- 29. MacIntyre NR, Sessler CN. Are there benefits or harm from pressure targeting during lung-protective ventilation? *Respir Care*. 2010;55(2):175-180.
- Slutsky AS, Ranieri VM. Ventilatorinduced lung injury. N Engl J Med. 2013;369(22):2126-2136.
- Ward ME, Corbeil C, Gibbons W, Newman S, Macklem PT. Optimization of respiratory muscle relaxation during mechanical ventilation. *Anesthesiology*. 1988;69(1):29-35.
- 32. Cinnella G, Conti G, Lofaso F, et al. Effects of assisted ventilation on the work of breathing: volume-controlled versus pressure-controlled ventilation. *Am J Respir Crit Care Med.* 1996;153(3): 1025-1033.
- 33. Yoshida T, Uchiyama A, Matsuura N, Mashimo T, Fujino Y. Spontaneous breathing during lung-protective ventilation in an experimental acute lung injury model: high transpulmonary pressure associated with strong spontaneous breathing effort may worsen lung injury. Crit Care Med. 2012;40(5): 1578-1585.
- 34. Yoshida T, Uchiyama A, Matsuura N, Mashimo T, Fujino Y. The comparison of spontaneous breathing and muscle paralysis in two different severities of experimental lung injury. *Crit Care Med.* 2013;41(2):536-545.
- Richard JC, Lyazidi A, Akoumianaki E, et al. Potentially harmful effects of inspiratory synchronization during pressure preset ventilation [published correction appears in *Intensive Care Med*. 2013;39(12):2241]. *Intensive Care Med*. 2013;39(11):2003-2010.
- Brochard L, Lellouche F. Pressure support ventilation. In: Tobin MJ, ed. *Principles and Practice of Mechanical Ventilation.* 3rd ed. New York, NY: McGraw-Hill; 2013:199-225.

- Marini JJ. Point: is pressure assist-control preferred over volume assist-control mode for lung protective ventilation in patients with ARDS? Yes. *Chest.* 2011; 140(2):286-290.
- Al-Saady N, Bennett ED. Decelerating inspiratory flow waveform improves lung mechanics and gas exchange in patients on intermittent positive-pressure ventilation. *Intensive Care Med.* 1985;11(2): 68-75.
- Davis K Jr, Branson RD, Campbell RS, Porembka DT. Comparison of volume control and pressure control ventilation: is flow waveform the difference? *J Trauma*. 1996;41(5):808-814.
- 40. Prella M, Feihl F, Domenighetti G. Effects of short-term pressure-controlled ventilation on gas exchange, airway pressures, and gas distribution in patients with acute lung injury/ARDS: comparison with volume-controlled ventilation. *Chest.* 2002;122(4):1382-1388.
- Rappaport SH, Shpiner R, Yoshihara G, Wright J, Chang P, Abraham E. Randomized, prospective trial of pressurelimited versus volume-controlled ventilation in severe respiratory failure. *Crit Care Med.* 1994;22(1):22-32.
- Nilsestuen JO, Hargett KD. Using ventilator graphics to identify patientventilator asynchrony. *Respir Care*. 2005;50(2):202-234.
- MacIntyre NR, McConnell R, Cheng KC, Sane A. Patient-ventilator flow dyssynchrony: flow-limited versus pressure-limited breaths. *Crit Care Med.* 1997;25(10):1671-1677.
- 44. Yang LY, Huang YCT, Macintyre NR. Patient-ventilator synchrony during pressure-targeted versus flow-targeted small tidal volume assisted ventilation. *J Crit Care*. 2007;22(3):252-257.
- 45. Kallet RH, Campbell AR, Alonso JA, Morabito DJ, Mackersie RC. The effects of pressure control versus volume control assisted ventilation on patient work of breathing in acute lung injury and acute respiratory distress syndrome. *Respir Care*. 2000;45(9):1085-1096.
- Chiumello D, Pelosi P, Calvi E, Bigatello LM, Gattinoni L. Different modes of assisted ventilation in patients with acute respiratory failure. *Eur Respir J.* 2002;20(4):925-933.
- 47. Kallet RH, Campbell AR, Dicker RA, Katz JA, Mackersie RC. Work of breathing during lung-protective ventilation in patients with acute lung injury and acute respiratory distress syndrome: a comparison between volume and pressure-regulated breathing modes. *Respir Care.* 2005;50(12):1623-1631.
- Chatmongkolchart S, Williams P, Hess DR, Kacmarek RM. Evaluation of inspiratory rise time and inspiration termination criteria in new-generation mechanical ventilators: a lung model study. *Respir Care*. 2001;46(7):666-677.
- Higgins JP, Altman DG, Gøtzsche PC, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assess-

ing risk of bias in randomised trials. *BMJ*. 2011;343:d5928.

- 50. Castellana FB, Malbouisson LM, Carmona MJ, Lopes CR, Auler Júnior JO. Comparison between pressure controlled and controlled mandatory ventilation in the treatment of postoperative hypoxemia after myocardial revascularization [in Portuguese]. *Rev Bras Anestesiol.* 2003;53(4):440-448.
- 51. Ge Y, Wan Y, Wang DQ, Su XL, Li JY, Chen J. Treatment of acute respiratory distress syndrome using pressure and volume controlled ventilation with lung protective strategy [in Chinese]. *Zhongguo Wei Zhong Bing Ji Jiu Yi Xue*. 2004;16(7):424-427.
- Gritsan A, Gazenkampf A, Dovbish N. Analysis of artificial respiration, controlled volume and pressure, in patients with hemorrhagic stroke. *Intensive Care Med.* 2012;38(suppl 1):S163.
- Mercat A, Graïni L, Teboul JL, Lenique F, Richard C. Cardiorespiratory effects of pressure-controlled ventilation with and without inverse ratio in the adult respiratory distress syndrome. *Chest.* 1993;104(3):871-875.
- 54. Lessard MR, Guérot E, Lorino H, Lemaire F, Brochard L. Effects of pressure-controlled with different I:E ratios versus volume-controlled ventilation on respiratory mechanics, gas exchange, and hemodynamics in patients with adult respiratory distress syndrome. *Anesthesiology*. 1994;80(5):983-991.
- 55. Vallverdu I, Bak E, Subirana M, et al. Acute effects of volume-controlled ventilation with peep and pressurecontrolled ventilation in ARDS. Analysis of gas exchange, hemodynamics and pulmonary mechanics. *Med Intensiva*. 1994;18(3):106-113.
- Mancebo J, Vallverdú I, Bak E, et al. Volume-controlled ventilation and pressure-controlled inverse ratio ventilation: a comparison of their effects in ARDS patients. *Monaldi Arch Chest Dis.* 1994;49(3):201-207.
- Auler Júnior JO, Carmona MJ, Silva MH, Silva AM, do Amaral RV. Haemodynamic effects of pressure-controlled ventilation versus volume-controlled ventilation in patients submitted to cardiac surgery. *Clin Intensive Care*. 1995;6(3):100-106.
- Castañón-González JA, León-Gutiérrez MA, Gallegos-Pérez H, Pech-Quijano J, Martínez-Gutíerrez M, Olvera-Chávez A. Pulmonary mechanics, oxygenation index, and alveolar ventilation in patients with two controlled ventilatory modes. A comparative crossover study [in Spanish]. Cir Cir. 2003;71(5):374-378.
- Kiehl M, Schiele C, Stenzinger W, Kienast J. Volume-controlled versus biphasic positive airway pressure ventilation in leukopenic patients with severe respiratory failure. *Crit Care Med.* 1996;24(5):780-784.
- 60. Yang YM, Huang WD, Shen MY, Xu ZR. Comparative study of pressure-control ventilation and volume-control ventilation in treating traumatic acute respiratory

distress syndrome. *Chin J Traumatol*. 2005;8(1):36-38.

- Armstrong BW Jr, MacIntyre NR. Pressure-controlled, inverse ratio ventilation that avoids air trapping in the adult respiratory distress syndrome. *Crit Care Med.* 1995;23(2):279-285.
- Sharma S, Mullins RJ, Trunkey DD. Ventilatory management of pulmonary contusion patients. *Am J Surg.* 1996;171(5):529-532.
- Karakurt Z, Yarkin T, Altinöz H, et al. Pressure vs. volume control in COPD patients intubated due to ARF: a casecontrol study. *Tuberk Toraks*. 2009;57(2): 145-154.
- Tharratt RS, Allen RP, Albertson TE. Pressure controlled inverse ratio ventilation in severe adult respiratory failure. *Chest.* 1988;94(4):755-762.
- Abraham E, Yoshihara G. Cardiorespiratory effects of pressure controlled ventilation in severe respiratory failure. *Chest.* 1990;98(6):1445-1449.
- 66. Muñoz J, Guerrero JE, Escalante JL, Palomino R, De La Calle B. Pressure-

controlled ventilation versus controlled mechanical ventilation with decelerating inspiratory flow. *Crit Care Med.* 1993; 21(8):1143-1148.

- Poelaert JI, Visser CA, Everaert JA, Koolen JJ, Colardyn FA. Acute hemodynamic changes of pressure-controlled inverse ratio ventilation in the adult respiratory distress syndrome. A transesophageal echocardiographic and Doppler study. *Chest.* 1993;104(1): 214-219.
- Clarke JP. The effects of inverse ratio ventilation on intracranial pressure: a preliminary report. *Intensive Care Med*. 1997;23(1):106-109.
- Zavala E, Ferrer M, Polese G, et al. Effect of inverse I:E ratio ventilation on pulmonary gas exchange in acute respiratory distress syndrome. *Anesthesiology*. 1998;88(1):35-42.
- Jung SH, Choi WJ, Lee JA, et al. Comparison of respiratory mechanics and gas exchange between pressurecontrolled and volume-controlled ventilation [in Korean]. *Tuberc Respir Dis.* 1999;46(5):662-673.

- Kim HC, Park SJ, Park JW, et al. Difference in patient's work of breathing between pressure-controlled ventilation with decelerating flow and volumecontrolled ventilation with constant flow during assisted ventilation [in Korean]. *Tuberc Respir Dis*. 1999;46(6): 803-810.
- Wang SH, Wei TS. The outcome of early pressure-controlled inverse ratio ventilation on patients with severe acute respiratory distress syndrome in surgical intensive care unit. *Am J Surg.* 2002;183(2):151-155.
- Razek AA, Marey T, El Shafei MN, Mansour EE, El Masry A. Ventilation mode: volume targeted or pressure targeted for patients following live donor liver transplantation (LDLT). *Egypt J Anaesth.* 2008;24:161-176.
- Othman MM, Farid AM, Mousa SA, Sultan MA. Hemodynamic effects of volume-controlled ventilation versus pressure-controlled ventilation in head trauma patients: a prospective crossover pilot study. *ICU Director*. 2013;4(5):223-231.